[
    [
        {
            "time": "",
            "original_text": "石药集团：港股医药一哥能否回A成下一个“恒瑞”？",
            "features": {
                "keywords": [
                    "石药集团",
                    "港股",
                    "医药",
                    "回A",
                    "恒瑞"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "石药集团：港股医药一哥能否回A成下一个“恒瑞”？",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "200家国内药企排名公布，这些企业上榜（附名单）",
            "features": {
                "keywords": [
                    "国内药企",
                    "排名",
                    "榜单"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "200家国内药企排名公布，这些企业上榜（附名单）",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "恒瑞医药：85倍PE，10年10倍，高ROE凭的是什么？",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "PE",
                    "ROE",
                    "长期增长"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药：85倍PE，10年10倍，高ROE凭的是什么？",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "9月融券余额连破两关至850多亿元 中芯国际、恒瑞医药融券净卖出额居前",
            "features": {
                "keywords": [
                    "融券余额",
                    "中芯国际",
                    "恒瑞医药",
                    "净卖出额"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "9月融券余额连破两关至850多亿元 中芯国际、恒瑞医药融券净卖出额居前",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "[浙商医药|周报]推荐Q3业绩高增长板块（API、CXO、检测），关注新冠疫苗Q4进展",
            "features": {
                "keywords": [
                    "浙商医药",
                    "周报",
                    "Q3业绩",
                    "API",
                    "CXO",
                    "检测",
                    "新冠疫苗",
                    "Q4进展"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[浙商医药|周报]推荐Q3业绩高增长板块（API、CXO、检测），关注新冠疫苗Q4进展",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]